BeyondSpring Inc. (BYSI)
NASDAQ: BYSI · Real-Time Price · USD
0.6056
-0.0034 (-0.56%)
At close: Oct 9, 2026, 4:00 PM EDT
0.6690
+0.0634 (10.47%)
After-hours: Oct 9, 2026, 7:58 PM EDT
BeyondSpring Earnings Call Transcripts
Fiscal Year 2026
-
FDA granted Fast Track designation to plinabulin plus docetaxel for post-ICI non-squamous NSCLC, enabling expedited development. DUBLIN-4 phase III will enroll 442 patients globally, with interim analysis expected in 2028. Strategic transactions improve efficiency and reduce costs.